Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial

J Pinto-Fraga, A Enríquez-de-Salamanca, M Calonge… - The ocular …, 2018 - Elsevier
Purpose To evaluate the effect of 0.1%-fluorometholone (FML) on tear inflammatory
molecule levels after 22-days treatment in dry eye disease (DED) patients exposed to an …
被引用次数：67 相关文章

Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial

J Pinto-Fraga, A Enríquez-de-Salamanca… - The ocular …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the effect of 0.1%-fluorometholone (FML) on tear inflammatory
molecule levels after 22-days treatment in dry eye disease (DED) patients exposed to an …

[引用][C] Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial

J Pinto-Fraga, A Enríquez-de-Salamanca… - The Ocular …, 2018 - cir.nii.ac.jp
Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a
phase III clinical trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial.

J Pinto-Fraga, A Enríquez-de-Salamanca… - The Ocular …, 2018 - europepmc.org
PURPOSE: To evaluate the effect of 0.1%-fluorometholone (FML) on tear inflammatory
molecule levels after 22-days treatment in dry eye disease (DED) patients exposed to an …